Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
September 04, 2018
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
June 01, 2016
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
June 24, 2015
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beraprost-314d Added-on to Tyvaso® (BEAT)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2013
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2013
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2011
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2011
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2010
Lead Product(s) : Beraprost Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable